Beta Adrenergic Blockade for Prophylaxis Against Recurrent Myocardial Infarction and Sudden Death

  1. JOHN ROSS, JR., M.D., F.A.C.P.
  1. Department of Medicine, University of California San Diego,
    La Jolla, California

    Excerpt

    The findings of a multicenter study in which the beta adrenergic blocking agent practolol was used for prophylaxis against recurrent myocardial infarction and sudden death in a large, randomized clinical trial were reported recently in the British Medical Journal (1). The results appear to have important implications for the management of patients after myocardial infarction. Indeed, the authors conclude that "Patients should receive longterm beta adrenoreceptor blocking treatment after anterior myocardial infarction unless specific contraindications exist . . . to be initiated between a few days and a month after the infarct" (1). No firm recommendations were made for routine

    This 100-word excerpt has been provided in the absence of an abstract.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement